RNS & Investor News

2020

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2019

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2018

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2017

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2016

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2015

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2014

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

2013

Extension of LPLDL® into Dairy Products

12 February 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LPLDL® into a functional yogurt product in Uruguay, South America.

Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix.  There are no minimum sales targets in the licencing agreement.

Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LPLDL®'s presence into South America and extends its use into dairy products.  Granja Pocha was chosen as our partner to create a functional yogurt containing LPLDL® because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market.  The work carried out by Granja Pocha is a significant milestone as it extends the use of LPLDL® into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LPLDL® provide a unique format for customer to receive the cholesterol reducing benefits of LPLDL® and capitalises on a growing industry trend towards functional foods."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 

OptiBiotix Health plc
Stephen O'Hara, Chief Executive

www.optibiotix.com
Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

finnCap (Broker)

 

Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Tel: 020 7220 0500

goetzpartners securities Limited
Ulrich Kinzel

Tel: 020 3859 7725

Walbrook PR Ltd
Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.